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Controlling sexually transmitted Chlamydia trachomatis in 
Europe is important because it is one of the most common notifiable 
infections in many European and other industrialised countries. 
Prevalence is highest in young sexually active adults, with infection 
rates of 2-6% estimated in population-based studies among under 
30 year-olds in the Netherlands [1], Denmark [2], and the United 
Kingdom (UK) [3]. Untreated genital chlamydia infections can 
cause tubal infertility, ectopic pregnancy, and chronic pelvic pain 
in women and epididymo-orchitis in men [4]. During pregnancy, 
chlamydia infections are associated with adverse outcomes and 
neonatal infections [4]. HIV infection is also transmitted more 
easily in the presence of co-infection with Chlamydia [4].  
The Screening for Chlamydia Review in Europe (SCREen) project 
investigated public health activities that contribute to the control 
of sexually transmitted genital Chlamydia trachomatis in Europe. 
More than 80 experts from 29 European countries contributed to 
this project funded by the European Centre for Disease Prevention 
and Control (ECDC), which was carried out from November 2006 to 
January 2008. We also obtained information from the United States 
because it has the most longstanding national recommendations 
about chlamydia control. The results of this investigation have now 
been published as a technical report on the ECDC website [5]. 
The project included: a semi-structured questionnaire; in depth 
visits to four countries (Estonia, the Netherlands, Sweden and the 
United Kingdom (England)); and compilation of a health system 
profile, social, economic, demographic and health indicators, laws 
and policies about sexually transmitted infection control, current 
surveillance data and publications about chlamydia prevalence and 
sexual behaviour, if available, for each country. Each participating 
country was assigned to one of five categories according to the 
intensity of chlamydia control activities, based on information 
provided in the questionnaire. 
The study identified wide variation in the range and intensity of 
activities that contribute to the public health control of chlamydia. 
Chlamydia testing was widely available in most countries in a 
variety of settings, including gynaecology clinics in all participating 
countries. All but one country had facilities for nucleic acid 
amplification diagnostic tests, and all but four countries had a 
system for reporting surveillance data about diagnosed chlamydia 
infections. Seventeen countries had at least one guideline about 
the diagnosis and management of chlamydia infections but the 
settings targeted by the guidelines were not always those where 
chlamydia testing was most frequent.
The countries in Europe were classified as follows (Figure 1): 
Thirteen countries were categorised as having no organised 
chlamydia control activities because there were no case management 
guidelines. Five countries had case management guidelines for at 
least one group of professionals; in a further three countries the 
guidelines also specified measures including partner notification 
and offering chlamydia testing to people with other sexually 
transmitted infections to encourage case finding. In another six 
countries the guidelines recommended both partner notification 
and offering opportunistic chlamydia tests to identify infections in 
at least one group of asymptomatic individuals attending health 
care settings. Two countries reported that they had an ongoing or 
pilot programme that aimed to offer chlamydia screening tests to 
all sexually active women and men, under 25 years in one country 
and under 30 years in the other. 
F i g u r e
Category of chlamydia control activity by country and per capita gross 
domestic product in €, for countries participating in project SCREen
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No organised activity, per capita gross domestic product mean (Standard Deviation) €26,728 (21,180)
Case management, €21,786 (5,814)
Case finding, €20,950 (9,405)
Opportunistic testing, €24,733 (10,534)
Screening programme, €28,100 (1,131)
 No organised activity Case management Case finding Opportunistic Programme
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Economic resources and type of health care system did not 
seem to be the main drivers of decisions about the priority given 
to chlamydia control in Europe. Of 13 countries with no current 
chlamydia control activities, the per capita gross domestic product 
of four countries was in the top quintile for Europe. There were also 
countries with low to moderate per capita gross domestic product 
with guidelines for all practitioners that covered case finding for 
partners of infected cases and opportunistic testing for selected 
populations.
The results and recommendations from this project have 
been considered by an expert panel and will be used by ECDC to 
formulate recommendations to enhance chlamydia prevention and 
control in the European Union member states.
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